Anima Biotech: Translation Control Therapeutics




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Anima Biotech: Translation Control Therapeutics
Released on: October 24, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that control protein translation.
  • Summary
  • Participants
  • Company
Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that control protein translation. Yochi Slonim discusses with Fintan Walton thier novel drug discovery platform that enables a new therapeutic strategy to approach hard or undruggable protein targets where existing methods have failed for decades.
Yochi Slonim is a serial entrepreneur with a track record of over 30 years in software and biotech. He co-founded Anima in 2005 and as CEO raised multiple rounds of capital and has been driving its drug discovery platform vision, development and business. Prior to Anima, Yochi has built several companies from their early stage, through all stages of product development, marketing and sales and eventually turned them into successful large exits. ? He was a co-founder of Mercury Interactive. As CTO and VP R&D from the company's early days he created product vision and strategy and led a multi-product organization of 200 developers. After going public and reaching revenues of over $1B annually, Mercury was acquired by HP for $4.5B. As Senior VP of products and marketing for Tecnomatix, a public NASDAQ company, he led a 500 people organization of 4 divisions that generated revenues of $100m until the company was acquired by UGS for $230m. In 2000, Yochi was founder and CEO of Identify. The company reached revenues of $50m in in less than 5 years and was acquired by BMC in 2006 for $150m in cash. Yochi founded ffwd.me (www.ffwd.me), a unique startup acceleration program where he led a team that worked with over 25 startups in diverse areas and technologies, developing strategy, products and go to market operations while raising multiple rounds of financing from VCs and private investors.
Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that control protein translation. Our novel drug discovery platform enables a new therapeutic strategy to approach hard or undruggable protein targets where existing methods have failed for decades. Our platform is enabled by a breakthrough, patented technology. Anima's Protein Synthesis Monitoring (PSM) technology enables for the first time the visualization and monitoring of protein synthesis by ribosomes in living cells in real time. We use this information in specialized high content screening methods to discover molecules that regulate protein translation, correcting problems in over-expression or under-expression of target proteins. The platform is the result of over a decade of development in collaboration with a broad network of 17 leading academia and research institutions that have validated and expanded the scope and reach of our technology. Anima's drug discovery pipeline is currently focused on three outstanding therapeutic areas where the underlying cause of the disease is closely linked to protein translation: Fibrosis (regulation of Collagen type I synthesis), Viral Infections (RSV - modulation of host mechanisms involved in virus replication) and Autism (regulation of protein synthesis in Synapses.) Protein translation is a major biological process and the ability to control it opens a new therapeutic strategy for many additional diseases. We seek to maximize the therapeutic potential of our platform by partnering with pharma companies in their drug discovery programs.